Cote d'Ivoire vs United Arab Emirates: Antiretroviral therapy coverage
Cote d'Ivoire
78.0%
in 2024
United Arab Emirates
77.0%
in 2024
Cote d'Ivoire rank
57th
United Arab Emirates rank
59th
Antiretroviral therapy coverage over time
- Cote d'Ivoire
- United Arab Emirates
How they compare
Cote d'Ivoire currently reports 78.0% against 77.0% in United Arab Emirates, a difference of 1.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was United Arab Emirates ahead.
Cote d'Ivoire ranks 57th and United Arab Emirates ranks 59th of 143 countries.
Across the 3 decades both report, Cote d'Ivoire averaged higher in 1 and United Arab Emirates in 2.
Head to head by decade
| Decade | Cote d'Ivoire | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.9% | 19.0% | 15.1% | United Arab Emirates |
| 2010s | 35.8% | 27.1% | 8.7% | Cote d'Ivoire |
| 2020s | 71.4% | 73.6% | 2.2% | United Arab Emirates |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage, Cote d'Ivoire or United Arab Emirates?
- Cote d'Ivoire, at 78.0% against 77.0% in United Arab Emirates as of 2024.
- What is the difference in antiretroviral therapy coverage between Cote d'Ivoire and United Arab Emirates?
- 1.0%, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Cote d'Ivoire and United Arab Emirates?
- 25 years are reported by both, from 2000 to 2024.
- How do Cote d'Ivoire and United Arab Emirates rank globally for antiretroviral therapy coverage?
- Cote d'Ivoire ranks 57th and United Arab Emirates ranks 59th of 143 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage (% of people living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.